Booth Gardner Parkinson’s Care Center is conducting a double-blind, placebo-controlled, randomized, 18-month Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson’s Disease (PD).
Who may be eligible to participate?
- Between 40 to 70 years of age
- Have been diagnosed with PD within 2 years of Baseline Visit
- Study participant must never have taken medications for the treatment of motor symptoms of PD
Other inclusion/exclusion criteria apply.
What does participation involve?
The study consists of three periods:
- Screening Period (1 month)
- Study Treatment Period (18 months)
- Safety Follow-up (SFU) Period (1 month)
Oral UCB0599 capsules or matching placebo capsules will be administered twice per day during the Study Treatment Period, approximately 12 hours apart. Total duration of study participation will last for approximately 21 months.
Investigator
Alida Griffith, MD
My Navigator